Exploring the role of the gut microbiome in modulating response to anti-PD-1 immunotherapy in melanoma patients

The gut microbiome plays a crucial role in modulating the immune response to cancer immunotherapies, particularly anti-PD-1 inhibitors, which have revolutionized the treatment of melanoma. Despite the success of these therapies in some patients, the response remains highly variable. Recent studies suggest that the composition and diversity of the gut microbiome can influence the efficacy of anti-PD-1 therapy by shaping systemic immunity, particularly through its effects on T-cell activation and tumor microenvironment dynamics. Specific microbial species, such as Akkermansia muciniphila and Bifidobacterium, as well as microbial metabolites like short-chain fatty acids (SCFAs), have been associated with enhanced immune responses and improved treatment outcomes. Conversely, dysbiosis, or microbial imbalance, has been linked to resistance to immunotherapy. This review explores the mechanisms by which the microbiome influences immune responses and discusses strategies such as fecal microbiota transplantation (FMT), dietary interventions, and probiotics to modulate the microbiome and enhance melanoma treatment outcomes. Understanding the microbiome's role in immunotherapy could lead to more personalized, effective treatment strategies for melanoma and other cancers.